Journal of Clinical Endocrinology & Metabolism, Vol 75, 1574-1576, Copyright © 1992 by Endocrine Society

ARTICLES

Glucose regulation of the autoantigen GAD65 in human pancreatic islets

E Bjork, O Kampe, FA Karlsson, DG Pipeleers, A Andersson, C Hellerstrom and DL Eizirik
Department of Internal Medicine, University Hospital, Uppsala, Sweden.

Recent data suggest that the enzyme glutamic acid decarboxylase (GAD) may be a primary beta-cell antigen involved in the autoimmune response leading to insulin dependent diabetes mellitus (IDDM). Following three days culture of human islets at different glucose concentrations (5.6, 11 or 28 mM), there was a single 65 kDa/GAD band in the islet extracts, as assessed by immunoprecipitation both with serum from a newly diagnosed IDDM patient and a sheep anti-GAD serum. The synthesis of GAD was strongly stimulated at the higher glucose concentrations. Likewise, Western blot analysis indicated a glucose-induced increase of GAD in the islets. The data suggest that an enhanced function of human islet cells increases expression of GAD65. Possibly, this could exacerbate the autoimmune assault in the early stages of IDDM, and be of practical importance in attempts to ameliorate the autoimmune response towards the beta-cells in IDDM.

This article has been cited by other articles:

				D. Dabelea, R. B. D'Agostino Jr, E. J. Mayer-Davis, D. J. Pettitt, G. Imperatore, L. M. Dolan, C. Pihoker, T. A. Hillier, S. M. Marcovina, B. Linder, et al. Testing the Accelerator Hypothesis: Body size, {beta}-cell function, and age at onset of type 1 (autoimmune) diabetes Diabetes Care, February 1, 2006; 29(2): 290 - 294. [Abstract] [Full Text] [PDF]

				C. E.M. De Block, I. H. De Leeuw, and L. F. Van Gaal Impact of Overweight on Chronic Microvascular Complications in Type 1 Diabetic Patients Diabetes Care, July 1, 2005; 28(7): 1649 - 1655. [Abstract] [Full Text] [PDF]

				A. Pundziute-Lycka, L.-A. Persson, G. Cedermark, A. Jansson-Roth, U. Nilsson, V. Westin, and G. Dahlquist Diet, Growth, and the Risk for Type 1 Diabetes in Childhood: A matched case-referent study Diabetes Care, December 1, 2004; 27(12): 2784 - 2789. [Abstract] [Full Text] [PDF]

				K. Skak, C. F. Gotfredsen, D. Lundsgaard, J. B. Hansen, J. Sturis, and H. Markholst Improved {beta}-Cell Survival and Reduced Insulitis in a Type 1 Diabetic Rat Model After Treatment With a {beta}-Cell-Selective KATP Channel Opener Diabetes, April 1, 2004; 53(4): 1089 - 1095. [Abstract] [Full Text] [PDF]

				T. MARUYAMA, A. SHIMADA, A. KANATSUKA, A. KASUGA, I. TAKEI, J. YOKOYAMA, and T. KOBAYASHI Multicenter Prevention Trial of Slowly Progressive Type 1 Diabetes with Small Dose of Insulin (the Tokyo Study): Preliminary Report Ann. N.Y. Acad. Sci., November 1, 2003; 1005(1): 362 - 369. [Abstract] [Full Text] [PDF]

				I. M. Libman, M. Pietropaolo, S. A. Arslanian, R. E. LaPorte, and D. J. Becker Changing Prevalence of Overweight Children and Adolescents at Onset of Insulin-Treated Diabetes Diabetes Care, October 1, 2003; 26(10): 2871 - 2875. [Abstract] [Full Text] [PDF]

				Diabetes Prevention Trial-Type 1 Diabetes Study Gr Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus N. Engl. J. Med., May 30, 2002; 346(22): 1685 - 1691. [Abstract] [Full Text] [PDF]

				G. Napolitano, I. Bucci, C. Giuliani, C. Massafra, C. Di Petta, E. Devangelio, D. S. Singer, F. Monaco, and L. D. Kohn High Glucose Levels Increase Major Histocompatibility Complex Class I Gene Expression in Thyroid Cells and Amplify Interferon-{gamma} Action Endocrinology, March 1, 2002; 143(3): 1008 - 1017. [Abstract] [Full Text] [PDF]

				D. Pavlovic, M. Van De Winkel, B. Van der Auwera, M.-C. Chen, F. Schuit, L. Bouwens, and D. Pipeleers Effect of Interferon-{gamma} and Glucose on Major Histocompatibility Complex Class I and Class II Expression by Pancreatic {beta}- and Non-{beta}-Cells J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2329 - 2336. [Abstract] [Full Text] [PDF]